Short answer
Solid Biosciences Inc. (SLDB) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$55M
- −38.8% YoY · +3.4% QoQ
- EPS (diluted)
- −$0.36
- +7.7% YoY · +30.8% QoQ
Source: XBRL data from the Solid Biosciences Inc. (SLDB) Q2 2026 10-Q on SEC EDGAR. USD.
Solid Biosciences Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no commercial product revenue generated
- Net loss $54.8M vs $39.5M YoY, up 38.8%; operating expenses $57.4M vs $41.7M
- SGT-212 R&D $2.4M, up 106.5%; SGT-601 lowest at $0.02M, down 99.0%
- Cash, equivalents and securities $377.7M at June 30, 2026, funding operations into mid-2028
- Near-term catalysts: FDA SGT-003 meeting planned late Q4 2026; initial SGT-212 data anticipated Q1 2027
Risk Factors
- Net losses $111.5 million for six months ended June 30, 2026, versus $78.8 million in 2025
- Funding runway into mid-2028, with additional capital required thereafter
- Uninsured bank deposits exceeding the FDIC limit of $250,000, creating liquidity-access risk
- Non-human-primate sourcing constraints could delay IND-enabling studies and Candidate progression
- Two treatment-related serious adverse events previously disclosed in INSPIRE DUCHENNE, though both resolved
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Solid Biosciences Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.